T-DXd has already been approved by the FDA as a second Her2-directed therapy option for patients with unresectable, locally advanced or metastatic GC in 2021 and is currently under investigation as a combination therapy with immune checkpoint inhibitors [8,9]. This evidence concerns the gene ERBB2 and gastric cancer.